Simvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing mice
| Autor: | Durvanei Augusto Maria, M. C. Guido, Raul C. Maranhão, Iara Fabricia Kretzer, Thais C. Contente |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Simvastatin medicine.medical_treatment Melanoma Experimental Pharmaceutical Science Apoptosis Pharmacology lipid nanoparticles Immunoenzyme Techniques chemistry.chemical_compound Mice 0302 clinical medicine International Journal of Nanomedicine Drug Discovery Antineoplastic Combined Chemotherapy Protocols Tumor Cells Cultured Receptor Original Research Drug Synergism General Medicine Lipids Paclitaxel 030220 oncology & carcinogenesis Toxicity Female NEOPLASIAS OVARIANAS Adjuvant Injections Intraperitoneal medicine.drug endocrine system Blotting Western Biophysics Bioengineering complex mixtures cancer treatment statins Biomaterials 03 medical and health sciences medicine Animals Cell Proliferation Organic Chemistry Cholesterol LDL B16F10 melanoma Mice Inbred C57BL 030104 developmental biology chemistry Receptors LDL LDL receptor drug delivery Lipoprotein |
| Zdroj: | International Journal of Nanomedicine Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1178-2013 1176-9114 |
| Popis: | Iara F Kretzer,1,2 Durvanei A Maria,3 Maria C Guido,1 Thaís C Contente,1 Raul C Maranhão1,2 1Laboratory of Metabolism and Lipids, Heart Institute of the Medical School Hospital, 2Department of Clinical Chemistry, Faculty of Pharmaceutical Sciences, University of São Paulo, 3Biochemistry and Biophysics Laboratories, Butantan Institute, SãoPaulo, Brazil Purpose: Lipid nanoemulsions (LDEs) that bind to low-density lipoprotein (LDL) receptors used as carriers of paclitaxel (PTX) can decrease toxicity and increase PTX antitumoral action. The administration of simvastatin (Simva), which lowers LDL-cholesterol, was tested as an adjuvant to commercial PTX and to PTX associated with LDE (LDE-PTX). Materials and methods: B16F10 melanoma-bearing mice were treated with saline solution or LDE (controls), Simva, PTX, PTX and Simva, LDE-PTX, and LDE-PTX and Simva: PTX dose 17.5 µmol/kg (three intraperitoneal injections, 3 alternate days): Simva 50 mg/kg/day by gavage, 9 consecutive days. Results: Compared with saline controls, 95% tumor-growth inhibition was achieved by LDE-PTX and Simva, 61% by LDE-PTX, 44% by PTX and Simva, and 43% by PTX. Simva alone had no effect. Metastasis developed in only 37% of the LDE-PTX and Simva, 60% in LDE-PTX, and 90% in PTX and Simva groups. Survival rates were higher in LDE-PTX and Simva and in LDE-PTX groups. The LDE-PTX and Simva group presented tumors with reduced cellular density and increased collagen fibers I and III. Tumors from all groups showed reduction in immunohistochemical expression of ICAM, MCP-1, and MMP-9; LDE-PTX and Simva presented the lowest MMP-9 expression. Expression of p21 was increased in the Simva, LDE-PTX, and LDE-PTX and Simva groups. Inthe Simva and LDE-PTX and Simva groups, expression of cyclin D1, a proliferation and survival promoter of tumor cells, was decreased. Therapy with LDE-PTX and Simva showed negligible toxicity compared with PTX and Simva, which resulted in weight loss and myelosuppression. Conclusion: Simva increased the antitumor activity of PTX carried in LDE but not of PTX commercial presentation, possibly because statins increase the expression of LDL receptors that internalize LDE-PTX. Keywords: lipid nanoparticles, drug delivery, statins, cancer treatment, B16F10 melanoma |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|